QUANTRES ASSET MANAGEMENT Ltd increased its stake in Pfizer Inc. (NYSE:PFE) by 302.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,800 shares of the biopharmaceutical company’s stock after purchasing an additional 25,400 shares during the period. QUANTRES ASSET MANAGEMENT Ltd’s holdings in Pfizer were worth $1,224,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Peregrine Asset Advisers Inc. lifted its position in Pfizer by 0.5% in the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 35 shares during the last quarter. Northwest Quadrant Wealth Management LLC lifted its position in shares of Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 50 shares in the last quarter. Stone House Investment Management LLC lifted its position in shares of Pfizer by 1.0% during the second quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 72 shares in the last quarter. Highland Private Wealth Management lifted its position in shares of Pfizer by 0.8% during the second quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 76 shares in the last quarter. Finally, Autus Asset Management LLC lifted its position in shares of Pfizer by 1.2% during the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 78 shares in the last quarter. Institutional investors and hedge funds own 71.41% of the company’s stock.
In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 185,464 shares of company stock valued at $6,767,939. 0.06% of the stock is currently owned by company insiders.
Shares of Pfizer Inc. (PFE) traded down $0.43 during midday trading on Wednesday, hitting $36.32. The stock had a trading volume of 13,168,146 shares, compared to its average volume of 24,983,600. The company has a market cap of $216,030.00, a P/E ratio of 20.75, a price-to-earnings-growth ratio of 2.06 and a beta of 0.91. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. During the same period in the prior year, the business earned $0.47 EPS. The firm’s revenue was up .6% on a year-over-year basis. research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer declared that its Board of Directors has initiated a share buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd were issued a $0.34 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend was Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.74%. Pfizer’s dividend payout ratio is 77.71%.
PFE has been the topic of a number of recent research reports. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, November 16th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price on the stock in a research report on Thursday, November 23rd. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Saturday, November 25th. Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Finally, UBS Group set a $40.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and an average price target of $39.40.
COPYRIGHT VIOLATION NOTICE: “QUANTRES ASSET MANAGEMENT Ltd Buys 25,400 Shares of Pfizer Inc. (NYSE:PFE)” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/quantres-asset-management-ltd-has-1-22-million-position-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.